NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday that its board of directors has set the record and distribution dates for the spinoff of its wholly owned subsidiary, Myriad Pharmaceuticals.

The firm said that Myriad Genetics' shareholders of record on June 17 will receive on June 30 a pro-rata dividend of .25 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics held. Fractional shares will be paid in cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.